CA3079906A1 - Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer - Google Patents
Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer Download PDFInfo
- Publication number
- CA3079906A1 CA3079906A1 CA3079906A CA3079906A CA3079906A1 CA 3079906 A1 CA3079906 A1 CA 3079906A1 CA 3079906 A CA3079906 A CA 3079906A CA 3079906 A CA3079906 A CA 3079906A CA 3079906 A1 CA3079906 A1 CA 3079906A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- psma
- cancer
- derivative
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575460P | 2017-10-22 | 2017-10-22 | |
| US62/575,460 | 2017-10-22 | ||
| PCT/CA2018/051336 WO2019075583A1 (en) | 2017-10-22 | 2018-10-22 | NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3079906A1 true CA3079906A1 (en) | 2019-04-25 |
Family
ID=66173073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3079906A Pending CA3079906A1 (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200339625A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3700917A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7282792B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102884167B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111630059B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018352731B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3079906A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019075583A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| DK3498308T3 (da) | 2017-12-13 | 2025-01-02 | Sciencons AS | Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid |
| CA3136979A1 (en) * | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer |
| CN110317151B (zh) * | 2019-06-06 | 2022-06-24 | 原子高科股份有限公司 | 前列腺癌PET诊断试剂68Ga-HBBED-ANCP-PSMA及其制备方法和应用 |
| WO2020252598A1 (en) * | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| TWI908773B (zh) * | 2020-03-04 | 2025-12-21 | 日商日本醫事物理股份有限公司 | 化合物及放射性標誌化合物 |
| US20240018110A1 (en) * | 2020-12-16 | 2024-01-18 | The University Of British Columbia | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| WO2022167681A1 (en) * | 2021-02-08 | 2022-08-11 | Stichting Radboud Universitair Medisch Centrum | Psma-targeting ligands for multimodal applications |
| CN116940557A (zh) * | 2021-03-04 | 2023-10-24 | 日本医事物理股份有限公司 | 化合物及放射性标记化合物 |
| US20240174622A1 (en) | 2021-03-04 | 2024-05-30 | Nihon Medi-Physics Co., Ltd. | Compound and radioactive labeling compound |
| CN113372285B (zh) * | 2021-05-28 | 2024-06-18 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用 |
| JP2024532521A (ja) | 2021-09-03 | 2024-09-05 | 晶核生物医藥科技（南京）有限公司 | ペプチド－尿素誘導体、それを含む医薬組成物、及びそれらの使用 |
| CN115806529A (zh) * | 2021-09-15 | 2023-03-17 | 威智医药有限公司 | Psma结合剂及其用途 |
| WO2023083209A1 (zh) * | 2021-11-10 | 2023-05-19 | 苏州瑞核医药科技有限公司 | 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用 |
| EP4436979A4 (en) | 2021-11-26 | 2026-06-10 | Full Life Tech Uk Limited | Cleftable radioligands for targeting cell surface receptors and their uses |
| EP4536278A4 (en) | 2022-06-07 | 2026-08-12 | Actinium Pharmaceuticals Inc | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| TW202410923A (zh) * | 2022-09-09 | 2024-03-16 | 大陸商同宜醫藥（蘇州）有限公司 | 放射性核種偶聯藥物及其藥物組成物和應用 |
| CN116199736B (zh) * | 2023-03-01 | 2025-03-18 | 西南医科大学附属医院 | 一种DOTA-Te-PSMA化合物及其应用 |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
| CN116730983B (zh) * | 2023-08-10 | 2023-11-03 | 山东大学 | 一种靶向前列腺特异性抗原的化合物及其制备方法与应用 |
| US20250213705A1 (en) | 2023-08-23 | 2025-07-03 | Bright Peak Therapeutics Ag | Psma targeting ligands and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| AU2014336638C1 (en) * | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3400229B1 (en) | 2016-01-10 | 2024-03-06 | Provincial Health Services Authority | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| CN109982998A (zh) * | 2016-11-23 | 2019-07-05 | 癌靶技术有限责任公司 | 白蛋白结合psma抑制剂 |
| CA3060143A1 (en) * | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
-
2018
- 2018-10-22 AU AU2018352731A patent/AU2018352731B2/en active Active
- 2018-10-22 US US16/758,361 patent/US20200339625A1/en not_active Abandoned
- 2018-10-22 CN CN201880081367.7A patent/CN111630059B/zh active Active
- 2018-10-22 KR KR1020207014223A patent/KR102884167B1/ko active Active
- 2018-10-22 CA CA3079906A patent/CA3079906A1/en active Pending
- 2018-10-22 EP EP18868855.0A patent/EP3700917A4/en active Pending
- 2018-10-22 WO PCT/CA2018/051336 patent/WO2019075583A1/en not_active Ceased
- 2018-10-22 JP JP2020543658A patent/JP7282792B2/ja active Active
-
2023
- 2023-05-17 JP JP2023081323A patent/JP7592120B2/ja active Active
- 2023-07-07 US US18/219,458 patent/US20230348535A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7592120B2 (ja) | 2024-11-29 |
| EP3700917A4 (en) | 2021-08-04 |
| CN111630059A (zh) | 2020-09-04 |
| KR20200100043A (ko) | 2020-08-25 |
| JP2021503490A (ja) | 2021-02-12 |
| EP3700917A1 (en) | 2020-09-02 |
| WO2019075583A1 (en) | 2019-04-25 |
| AU2018352731A1 (en) | 2020-05-21 |
| KR102884167B1 (ko) | 2025-11-12 |
| US20200339625A1 (en) | 2020-10-29 |
| JP2023113695A (ja) | 2023-08-16 |
| CN111630059B (zh) | 2025-06-06 |
| US20230348535A1 (en) | 2023-11-02 |
| JP7282792B2 (ja) | 2023-05-29 |
| AU2018352731B2 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7592120B2 (ja) | 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物 | |
| US11951190B2 (en) | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer | |
| US20220202966A1 (en) | Positron emitting radionuclide labeled peptides for human upar pet imaging | |
| JP7805637B2 (ja) | がんに対するペプチド受容体を標的とした放射性核種療法の治療性能を改善するための構造最適化法 | |
| US12472272B2 (en) | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | |
| Ishizaki et al. | Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives | |
| US20250009911A1 (en) | DOTA-HYNIC-iPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN | |
| CA2464002C (en) | Pacap compositions and methods for tumor imaging and therapy | |
| JP2026506464A (ja) | 部位特異的ｕＰＡＲ標的化のための放射性核種標識ペプチドコンジュゲート | |
| WO2025171887A1 (en) | Radiolabeled complexes and pharmaceutical compositions including the same | |
| HK40080502B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241017 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241028 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250113 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250113 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250220 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250530 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250530 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251013 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251013 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251223 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260106 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20260421 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260519 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260519 |